Hosted on MSN4h
Citigroup Initiates Coverage of Candel Therapeutics (CADL) with Buy Recommendation
Fintel reports that on February 20, 2025, Citigroup initiated coverage of Candel Therapeutics (NasdaqGM:CADL) with a Buy ...
My Mother Made a Nearly Impossible Rule About Family Visits. I’m Going to Lose It.
The trouble is, she is getting increasingly upset with me each time I cancel. When I called this past weekend to let her know ...
Candel Therapeutics: Entering Its Pivotal Year
Candel Therapeutics' lead candidate CAN-2409 shows promising results in several indications. Find out why I rate CADL stock ...
Scientific American3d
A Vaccine for the Dreaded Norovirus Is Closer Than Ever
Norovirus infection rates are extremely high this year, raising the question: Why can’t a vaccine protect us from the stomach ...
Covid-era mask warning issued to Brits as 'quad-demic' hits UK with viruses surging
Cases of adenovirus, HMPV, parainfluenza and rhinovirus have surged in just a few days - all of which can cause serious ...
Hosted on MSN1d
Canaccord Genuity Initiates Coverage of Candel Therapeutics (CADL) with Buy Recommendation
Fintel reports that on February 19, 2025, Canaccord Genuity initiated coverage of Candel Therapeutics (NasdaqGM:CADL) with a ...
中国日报网1d
Respiratory infections fall; expert cautions on risks
With rising temperatures and the start of the spring semester, Peng said that campuses will be coping with the increased risk ...
Portfolio9h
Respiratory infections rise in Hungary after promising decline
After a promising decline on the 6th week of 2025, the number of people seeking medical help with respiratory infection, ...
Brits issued Covid-era mask warning as 'quad-demic' hits UK
Brits have been warned they face a four-pronged assault from four viruses, with positivity rates increasing across the board ...
Medscape1d
Vasculitis Patients Need Multiple COVID Vaccine Boosters
Multiple vaccine shots are needed to boost vasculitis patients’ immunity against COVID, especially if they have been treated ...
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...
News Medical on MSN2d
Gene therapy breakthrough offers hope for severe Dravet syndrome cases
AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...